Authors
Sukovatykh B.S. 1, Bolomatov N.V.2, 4, Serednitsky A.V.3, Sidorov D.V.3, Sukovatykh M.B.1, Pashkov V.M.1, Gvozdeva E.G.3
1 Kursk State Medical University, Kursk
2 Kursk City Clinical Hospital of Emergency Medical Care, Kursk
3 Oryol Regional Clinical Hospital, Oryol
4 Pirogov National Medical and Surgical Center, Moscow
Abstract
Objective: to study the effectiveness of eptifibatide in the prevention of thrombotic complications in the endovascular treatment of acute myocardial infarction against the background of coronavirus infection.
Materials and methods: а retrospective analysis of the results of emergency intervention was performed in 60 patients with acute occlusion of the infarct-dependent artery against the background of concomitant new coronary infection COVID-19. The patients were divided into 2 statistically homogeneous groups of 30 people each. In the first (main) group, the drug «Eptifibatide» was administered to patients before performing percutaneous coronary intervention, in the second (control) group, the drug was not used. The efficiency of restoring coronary blood flow was determined according to the evaluation method by the number of coronary angiography frames for which the revascularized artery was filled with contrast agent: up to 20 frames — complete restoration of coronary blood flow, from 20 to 40 — partial, over 40 frames — unrecoverable. The number of thrombotic complications and adverse events (fatal outcome, repeated myocardial infarction, repeated emergency intervention) was recorded after the intervention.
Results: In the first group, complete restoration of coronary blood flow was achieved in 60%, partial — in 30%, blood flow was not restored — 10%, and in the second group, respectively, in 30%, 50% and 20% of patients. In the first group, thrombotic complications developed in 6.7%, and in the second group in 26.7%, adverse events occurred respectively in 10% and 23.3% of patients.
Conclusion: the use of the drug “Eptifibatide” in endovascular treatment of myocardial infarction against the background of coronavirus infection accelerates coronary blood flow, reduces the number of thrombotic complications and adverse events.
Keywords: acute myocardial infarction, coronavirus infection, coronary artery thrombosis, percutaneous coronary intervention, platelet receptor II B — III A blockers, eptifibatide.
References
1. Tereshchenko AS, Merkulov EV, Samko AN. The use of glycoprotein IIb/IIIa receptor inhibitors in patients with ST-segment elevation myocardial infarction and primary percutaneous coronary intervention. Rational Pharmacotherapy in Cardiology/ 2019; 15(6): 918-927. (In Russ.) doi: 10.20996/1819-6446-2019-15-6-918-927.
2. Tereshchenko AS, Merkulov EV, Shakhnovich RM, Samko AN. Manual thromboextraction in patients with acute myocardial infarction with ST segment elevation. Atherothrombosis. 2016; 1: 39-50. (In Russ.) doi: 10.21518/2307-1109-2016-1-39-49.
3. Frolov AA, Pochinka IG, Shakhov BE, Sharabrin EG, Kuzmichev KV. The phenomenon of coronary microvascular obstruction (no-reflow) during percutaneous coronary interventions in patients with myocardial infarction. Pathology of blood circulation and cardiac surgery. 2020; 24(1): 18-27. (In Russ.)
4. Iskhakov MM, Sayfullin RR, Yagafarov IR, et al. Primary percutaneous coronary interventions in patients with ST-segment elevation myocardial infarction complicated by the “no-reflow” phenomenon. Kazan Medical Journal. 2015; 96(3): 326. (In Russ.)
5. De Luca L, Sardella G, Davidson CJ, et al. Impact of intracoronary aspiration thrombectomy uring primary angioplasty on left ventricular remodeling in patients with anterior STelevation myocardial infarction. Heart. 2006; 92: 951-957.
6. Teplyakov DV, Nazarov EM, Tkhagapsov AZ, Volkov AV. Experience of using the 2b/3a receptor blocker eptifibatide in elderly patients with acute coronary syndrome during percutaneous coronary intervention. The successes of gerontology. 2016; 29(1): 164-167. (In Russ.)
7. Mahmoudi M, Delhaye C, Wakabayashi K, et al. Integrilin in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction. J Interv Cardiol. 2011; 24(4): 351-6. doi: 10.1111/j.1540-8183.2011.00632.x.
8. Shevchenko YuL, Stoiko YuM, Gudymovich V.G. Endothelium as a target of pathological effects of viral infection. Bulletin of the NMHC named after N.I. Pirogov. 2022; 17(2): 11-16. (In Russ.) doi: 10.25881/20728255_2022_17_2_11.
9. Gerasimov AM, Tereshchenko AS, Merkulov EV, Samko AN. The phenomenon of non-restored coronary blood flow (NO-REFLOW) in the practice of endo-vascular surgeon. Bulletin of Radiology and Radiology. 2014; 1: 51-55. (In Russ.)
